Recombinant human alpha-2a interferon promotes an atypical process of mast cell secretion with ultrastructural features suggestive for piecemeal degranulation

The Effect of Heat Shock on Production of Recombinant Human Interferon Alpha 2a (rhIFN α -2a) by Escherichia coli

Recombinant human interferon alpha 2a (rhIFN α -2a) production and cell growth were monitored in a set of genetically modified E. coli strains (MSD1519, MSD1520, MSD 1521, MSD 1522, MSD 1523) producing rhIFN α -2a. The growth was followed at OD 600 nm, changes in cell physiology were detected by pyrolysis mass spectrometry (PyMS) of cell biomass and recombinant protein production was determined...

the effect of heat shock on production of recombinant human interferon alpha 2a (rhifn α -2a) by escherichia coli

recombinant human interferon alpha 2a (rhifn α -2a) production and cell growth were monitored in a set of genetically modified e. coli strains (msd1519, msd1520, msd 1521, msd 1522, msd 1523) producing rhifn α -2a. the growth was followed at od 600 nm, changes in cell physiology were detected by pyrolysis mass spectrometry (pyms) of cell biomass and recombinant protein production was determined...

A Simplified Process for Purification and Refolding of Recombinant Human Interferon-α2b

Background: Interferon α-2b is a vital biotherapeutic produced through the recombinant DNA technology in E. coli. The recombinant IFN-α2b normally appears as intercellular IBs, which requires intensive refolding and purification steps. Method: Purification of IFN-α2b from solubilized IB was performed using two-phase extraction. To optimize refolding conditions, the effects of pH and different a...

[Treatment of lymphangioma with alpha-2a-interferon]

OBJECTIVE: To describe the results of the use of alpha-2a-interferon in the treatment of inoperable childhood lymphangiomas refractory to other therapeutic management. METHOD: We reviewed the literature about pathogenic events and the treatments available for lymphangiomas. Based on that, we used alpha-2a-interferon at a dose of 3 million units/m(2)/day administered subcutaneously to patients w...

[The binding activity of recombinant human interferon alpha-2a to its receptor on FL cells].